<DOC>
	<DOCNO>NCT00984815</DOCNO>
	<brief_summary>The purpose study evaluate safety long-term treatment HZT-501 , fixed-dose combination oral tablet 800 mg ibuprofen 26.6 mg famotidine patient require long-term NSAID treatment .</brief_summary>
	<brief_title>Safety Study HZT-501 Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment</brief_title>
	<detailed_description>HZT-501 , fixed-dose combination ibuprofen , pain inflammation relieve non-steroidal anti-inflammatory drug ( NSAID ) , famotidine , histamine type 2 receptor antagonist ( H2RA ) , develop treatment patient sign symptom osteoarthritis , rheumatoid arthritis , mild moderate pain dysmenorrhea risk develop ibuprofen-associated upper gastrointestinal ulcer .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Nociceptive Pain</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Patient capable understand purpose risk study able provide write Informed Consent . Patient male female , age 40 80 year age . Patient expect require daily administration NSAID least coming year condition include limited : osteoarthritis , rheumatoid arthritis , chronic low back pain , chronic regional pain syndrome , chronic soft tissue pain . Female patient childbearing potential male patient partner childbearing potential must agree use medically acceptable method contraception throughout entire study period . Patient willing able comply prescribe treatment protocol evaluation . Patient history experience follow : NSAIDassociated and/or primary peptic ulcer diseaseassociated serious gastrointestinal complication perforation ulcer , gastric outlet obstruction due ulcer , and/or acute gastrointestinal bleeding NSAIDinduced asthma exacerbation , acute renal failure , interstitial nephritis , and/or hepatitis Malignant disease gastrointestinal tract Erosive esophagitis Coronary artery bypass graft ( CABG ) surgery within 14 day prior study Day 0 Uncontrolled diabetes mellitus evidence Hemoglobin A1c &gt; 7 % Known history human immunodeficiency virus ( HIV ) , hepatitis B , and/or hepatitis C Patient active cardiac , renal , and/or hepatic disease , evidence : Creatinine clearance &lt; 45 mL/min ( base CockroftGault formula ) Screening Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal Screening History acute myocardial infarction , unstable cardiac arrhythmia , and/or stroke within 6 month prior study entry Uncontrolled congestive heart failure Uncontrolled hypertension Patient currently participate investigational drug study , patient participate investigational drug study within 30 day prior study entry . Female patient positive urine pregnancy test Screening and/or Study Day 0 . Patient concomitant disease condition , opinion Investigator , could interfere conduct study could put patient unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>NSAID</keyword>
	<keyword>Chronic Pain</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>